The dynamics of compound, transcript, and protein effects after treatment with 2OMePS antisense oligonucleotides in mdx mice

Molecular Therapy Nucleic Acids

Volumn 3, Issue , 2014, Pages e148-

  Verhaart, Ingrid E C ^a   Van Vliet Van Den Dool, Laura ^a   Sipkens, Jessica A ^b   De Kimpe, Sjef J ^b   Kolfschoten, Ingrid G M ^b   Van Deutekom, Judith C T ^b   Liefaard, Lia ^c   Ridings, Jim E ^c   Hood, Steve R ^c   Aartsma Rus, Annemieke ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b Prosensa Therapeutics   (Netherlands)

^c GLAXOSMITHKLINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

2' O METHYL OLIGONUCLEOTIDE PHOSPHOROTHIOATE; ANTISENSE OLIGONUCLEOTIDE; DYSTROPHIN; OLIGONUCLEOTIDE PHOSPHOROTHIOATE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTISENSE THERAPY; ARTICLE; CONTROLLED STUDY; DIAPHRAGM; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG HALF LIFE; DUCHENNE MUSCULAR DYSTROPHY; EXON; EXON SKIPPING; HEART; KIDNEY; LIVER; MOLECULAR DYNAMICS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUADRICEPS FEMORIS MUSCLE; SKELETAL MUSCLE; TRICEPS BRACHII MUSCLE; TURNOVER TIME; BODY WEIGHT; CELL REGENERATION; FEMALE; LIMIT OF DETECTION; MALE; PLASMA CLEARANCE; PROTEIN ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; X CHROMOSOME LINKED MUSCULAR DYSTROPHIC MOUSE;

EID: 84893906207     PISSN: None     EISSN: 21622531     Source Type: Journal    
DOI: 10.1038/mtna.2014.1     Document Type: Article

References (34)

1. Moat, SJ, Bradley, DM, Salmon, R, Clarke, A and Hartley, L (2013). Newborn bloodspot screening for Duchenne muscular dystrophy: 21 years experience in Wales (UK). Eur J Hum Genet 21: 1049-1053.
2. Mendell, JR and Lloyd-Puryear, M (2013). Report of MDA muscle disease symposium on newborn screening for Duchenne muscular dystrophy. Muscle Nerve 48: 21-26.
3. Emery, AE (2002). The muscular dystrophies. Lancet 359: 687-695.
4. Blake, DJ, Weir, A, Newey, SE and Davies, KE (2002). Function and genetics of dystrophin and dystrophin-related proteins in muscle. Physiol Rev 82: 291-329.
5. Sicinski, P, Geng, Y, Ryder-Cook, AS, Barnard, EA, Darlison, MG and Barnard, PJ (1989). The molecular basis of muscular dystrophy in the mdx mouse: a point mutation. Science 244: 1578-1580.
6. Torres, LF and Duchen, LW (1987). The mutant mdx: inherited myopathy in the mouse. Morphological studies of nerves, muscles and end-plates. Brain 110 (Pt 2): 269-299.
7. Banks, GB and Chamberlain, JS (2008). The value of mammalian models for duchenne muscular dystrophy in developing therapeutic strategies. Curr Top Dev Biol 84: 431-453.
8. Verhaart, IE and Aartsma-Rus, A (2012). Gene therapy for Duchenne muscular dystrophy. Curr Opin Neurol 25: 588-596.
9. Goemans, NM, Tulinius, M, van den Akker, JT, Burm, BE, Ekhart, PF, Heuvelmans, N et al. (2011). Systemic administration of PRO051 in Duchenne's muscular dystrophy. N Engl J Med 364: 1513-1522.
10. Cirak, S, Arechavala-Gomeza, V, Guglieri, M, Feng, L, Torelli, S, Anthony, K et al. (2011). Exon skipping and dystrophin restoration in patients with Duchenne muscular dystrophy after systemic phosphorodiamidate morpholino oligomer treatment: an open-label, phase 2, dose-escalation study. Lancet 378: 595-605.
11. Prosena. GSK and Prosensa announce primary endpoint not met in phase III study of drisapersen in patients with duchenne muscular dystrophy. .
12. Heemskerk, H, de Winter, C, van Kuik, P, Heuvelmans, N, Sabatelli, P, Rimessi, P et al. (2010). Preclinical PK and PD studies on 2'-O-methyl- phosphorothioate RNA antisense oligonucleotides in the mdx mouse model. Mol Ther 18: 1210-1217.
13. Heemskerk, H, de Winter, CL, van Ommen, GJ, van Deutekom, JC and Aartsma-Rus, A (2009). Development of antisense-mediated exon skipping as a treatment for duchenne muscular dystrophy. Ann N Y Acad Sci 1175: 71-79.
14. Heemskerk, HA, de Winter, CL, de Kimpe, SJ, van Kuik-Romeijn, P, Heuvelmans, N, Platenburg, GJ et al. (2009). In vivo comparison of 2'-O-methyl phosphorothioate and morpholino antisense oligonucleotides for Duchenne muscular dystrophy exon skipping. J Gene Med 11: 257-266.
15. Tanganyika-de Winter, CL, Heemskerk, H, Karnaoukh, TG, van Putten, M, de Kimpe, SJ, van Deutekom, J et al. (2012) Long-term exon skipping studies with 2'-O-methyl phosphorothioate antisense oligonucleotides in dystrophic mouse models. Mol Ther Nucleic Acids 1: e43.
16. Verhaart, IE, Heemskerk, H, Karnaoukh, TG, Kolfschoten, IG, Vroon, A, van Ommen, GJ et al. (2012). Prednisolone treatment does not interfere with 2'-O-methyl phosphorothioate antisense-mediated exon skipping in Duchenne muscular dystrophy. Hum Gene Ther 23: 262-273.
17. Verhaart, IE, Tanganyika-de Winter, CL, Karnaoukh, TG, Kolfschoten, IG, de Kimpe, SJ, van Deutekom, JC et al. (2013). Dose-dependent pharmacokinetic profiles of 2'-O-methyl phosphorothioate antisense oligonucleotidesin mdx mice. Nucleic Acid Ther 23: 228-237.
18. Brun, C, Suter, D, Pauli, C, Dunant, P, Lochmüller, H, Burgunder, JM et al. (2003). U7 snRNAs induce correction of mutated dystrophin pre-mRNA by exon skipping. Cell Mol Life Sci 60: 557-566.
19. Bish, LT, Sleeper, MM, Forbes, SC, Wang, B, Reynolds, C, Singletary, GE et al. (2012). Long-term restoration of cardiac dystrophin expression in golden retriever muscular dystrophy following rAAV6-mediated exon skipping. Mol Ther 20: 580-589.
20. Sharp, NJ, Kornegay, JN, Van Camp, SD, Herbstreith, MH, Secore, SL, Kettle, S et al. (1992). An error in dystrophin mRNA processing in golden retriever muscular dystrophy, an animal homologue of Duchenne muscular dystrophy. Genomics 13: 115-121.
21. Wang, Z, Tapscott, SJ, Chamberlain, JS and Storb, R (2011). Immunity and AAVMediated Gene Therapy for Muscular Dystrophies in Large Animal Models and Human Trials. Front Microbiol 2: 201.
22. Vulin, A, Barthélémy, I, Goyenvalle, A, Thibaud, JL, Beley, C, Griffith, G et al. (2012). Muscle function recovery in golden retriever muscular dystrophy after AAV1-U7 exon skipping. Mol Ther 20: 2120-2133.
23. Le Hir, M, Goyenvalle, A, Peccate, C, Précigout, G, Davies, KE, Voit, T et al. (2013). AAV genome loss from dystrophic mouse muscles during AAV-U7 snRNA-mediated exonskipping therapy. Mol Ther 21: 1551-1558.
24. Brown, DA, Kang, SH, Gryaznov, SM, DeDionisio, L, Heidenreich, O, Sullivan, S et al. (1994). Effect of phosphorothioate modification of oligodeoxynucleotides on specific protein binding. J Biol Chem 269: 26801-26805.
25. Yu, RZ, Kim, TW, Hong, A, Watanabe, TA, Gaus, HJ and Geary, RS (2007). Crossspecies pharmacokinetic comparison from mouse to man of a second-generation antisense oligonucleotide, ISIS 301012, targeting human apolipoprotein B-100. Drug Metab Dispos 35: 460-468.
26. Wu, B, Lu, P, Cloer, C, Shaban, M, Grewal, S, Milazi, S et al. (2012). Long-term rescue of dystrophin expression and improvement in muscle pathology and function in dystrophic mdx mice by peptide-conjugated morpholino. Am J Pathol 181: 392-400.
27. Alter, J, Lou, F, Rabinowitz, A, Yin, H, Rosenfeld, J, Wilton, SD et al. (2006). Systemic delivery of morpholino oligonucleotide restores dystrophin expression bodywide and improves dystrophic pathology. Nat Med 12: 175-177.
28. Wu, B, Lu, P, Benrashid, E, Malik, S, Ashar, J, Doran, TJ et al. (2010). Dose-dependent restoration of dystrophin expression in cardiac muscle of dystrophic mice by systemically delivered morpholino. Gene Ther 17: 132-140.
29. Betts, C, Saleh, AF, Arzumanov, AA, Hammond, SM, Godfrey, C, Coursindel, T et al. (2012). Pip6-PMO, A New Generation of Peptide-oligonucleotide Conjugates With Improved Cardiac Exon Skipping Activity for DMD Treatment. Mol Ther Nucleic Acids 1: e38.
30. Yin, H, Saleh, AF, Betts, C, Camelliti, P, Seow, Y, Ashraf, S et al. (2011). Pip5 transduction peptides direct high efficiency oligonucleotide- mediated dystrophin exon skipping in heart and phenotypic correction in mdx mice. Mol Ther 19: 1295-1303.
31. Spitali, P, van den Bergen, JC, Verhaart, IE, Wokke, B, Janson, AA, van den Eijnde, R et al. (2013). DMD transcript imbalance determines dystrophin levels. FASEB J 27: 4909-4916.
32. Mann, CJ, Honeyman, K, McClorey, G, Fletcher, S and Wilton, SD (2002). Improved antisense oligonucleotide induced exon skipping in the mdx mouse model of muscular dystrophy. J Gene Med 4: 644-654.
33. Yu, RZ, Baker, B, Chappell, A, Geary, RS, Cheung, E and Levin, AA (2002). Development of an ultrasensitive noncompetitive hybridization-ligation enzyme-linked immunosorbent assay for the determination of phosphorothioate oligodeoxynucleotide in plasma. Anal Biochem 304: 19-25.
34. Spitali, P, Heemskerk, H, Vossen, RH, Ferlini, A, den Dunnen, JT, 't Hoen, PA et al. (2010). Accurate quantification of dystrophin mRNA and exon skipping levels in duchenne muscular dystrophy. Lab Invest 90: 1396-1402.